The full results from Novavax’ Phase 3, randomized, observer-blinded, placebo-controlled trial conducted in more than 15,000 adults in the United Kingdom have been published in a manuscript posted to the preprint server medRxiv. Conclusions state that a two-dose regimen of Novavax’ COVID-19 vaccine candidate, NVX-CoV2373, conferred nearly 90% protection against a blend of prototype and variant COVID-19, demonstrated high efficacy against the B.1.1.7 variant, and demonstrated a reassuring safety profile. The study assessed efficacy during a period when the B.1.1.7 variant strain of the virus was emerging and circulating widely in the United Kingdom. It is now the most widely circulating variant strain of the virus in the United States.
The findings, detailed in ‘Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.1.7 Variant,’ have been submitted for peer-review publication and are now available online here. Initial findings from this study were shared on January 28 here.